What is it about?
Herein, the authors analyzedthe experimental and clinical evidence of the HMGB1-TLR pathway in epilepsy to summarize the theory of epileptogenesis and provideinsights into antiepileptic therapy in this novel field.
Featured Image
Why is it important?
Epilepsy is one of the most common serious neurological disorders, affecting over 70 million people world-wide. For treatment of epilepsy, antiepileptic drugs (AEDs) and surgeries are widely used. However, drug resistance and adverse effects indicate the need to develop targeted AEDs based on further exploration of the epileptogenic mechanism. Currently, many efforts have been made elucidate to the neuro inflammation theory in epileptogenesis, which may show potentialin treatment of epilepsy. In this respect, an important target protein, high mobility group box 1 (HMGB1), has received increased attention and has been developed rapidly. HMGB1 is expressed in various eukaryotic cells and localized in the cell nucleus. When HMGB1is released by injuries or diseases, it participates in inflammation. Recent studies suggest that HMGB1 via Toll-like receptor (TLR) pathways can trigger inflammatory responses and play an important role in epilepsy. In addition, studies of HMGB1 have shown its potential in treatment of epilepsy.
Perspectives
Current treatments for epilepsy have problems with drug resistance and adverse effects. Research on the HMGB1-TLR pathway of inflammation shows that it is closely related to the mechanism of epileptogenesis and has potential in the treatment of epilepsy. Although many studies have established a preliminary outline of the HMGB1-TLR pathway in epileptogenesis and potential treatment options, there are still many aspects that need further research. The ultimate goal of research on the HMGB1-TLR pathway in epilepsy is to elucidate the mechanisms of epileptogenesis and identify strategies for treatment of patients with epilepsy.
Dr. Shu Wang
Capital Medical University
Read the Original
This page is a summary of: The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy, Current Drug Targets, February 2021, Bentham Science Publishers,
DOI: 10.2174/1389450121999200729150443.
You can read the full text:
Resources
Contributors
The following have contributed to this page
